tirzepatide phase 3 mash Shows Superior Weight Loss Over Semaglutide in Trial Biomed Initiates Phase 3 Trials
Description
I dont understand why
More affordable alternatives may be available and worth discussing with a healthcare provider
In obesity patients in SURMOUNT3 and SURMOUNT4, a high rate of AEs of 87.1% and 81.0%, respectively, was observed, also with GI AEs being the most frequent system affected
If yours does not, supplementing with 1000 mcg of sublingual B12 daily is a reasonable precaution
A separate trial, SELECT, gave cardiologists a reason to pay attention
